智通财经APP获悉，根据2025年8月18日披露数据，中国电信（00728）、绿色动力环保（01330）、中 国神华（01088）位居港股通持股比例前3位，分别为74.69%、69.88%、68.38%。此外，中国人寿 （02628）、南方恆生科技（03033）、信达生物（01801）在最近有统计数据的5个交易日内，持股额增 幅最大，分别为+24.16亿元、+12.98亿元、+9.84亿元;快手-W（01024）、盈富基金（02800）、安踏体 育（02020）在最近有统计数据的5个交易日内，持股额减幅最大，分别为-27.47亿元、-25.56亿 元、-16.11亿元。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新持股比例排行（前20名） 3、港股通最近5个交易日减持榜（前10名） | 公司名称 | 持股额变动 | 持股数变动 | | --- | --- | --- | | 快手-W(01024) | -27.47亿元 | -3727.86万股 | | 盈富基金(02800) | -25.56亿元 | -9961.30万股 | | 安踏体育(02020) | -16.11亿元 | -1728. ...

Key Points - The top three stocks with net inflows from southbound funds are China Life (02628) with 1.58 billion, Southern Hang Seng Technology (03033) with 768 million, and Alibaba-W (09988) with 452 million [1][2] - The top three stocks with net outflows are Tencent Holdings (00700) with -1.20 billion, Anta Sports (02020) with -697 million, and Rongchang Biopharmaceutical (09995) with -584 million [1][2] - In terms of net inflow ratio, Datang Renewable (01798) leads with 74.45%, followed by Shenzhen Expressway (00548) with 50.53%, and Bosideng (03998) with 50.23% [1][3] - The top three stocks with the highest net outflow ratios are Chongqing Rural Commercial Bank (03618) at -58.46%, Kington Services (09666) at -54.34%, and Poly Property Group (00119) at -51.88% [1][3] Net Inflow Rankings - The top ten stocks by net inflow include: - China Life (02628): 1.58 billion, 34.91% increase, closing price 23.620 (+3.60%) [2] - Southern Hang Seng Technology (03033): 768 million, 14.65% increase, closing price 5.475 (-0.90%) [2] - Alibaba-W (09988): 452 million, 4.38% increase, closing price 121.800 (-1.54%) [2] - Other notable stocks include Li Auto-W (02015) with 349 million and AIA Group (01299) with 317 million [2] Net Outflow Rankings - The top ten stocks by net outflow include: - Tencent Holdings (00700): -1.20 billion, -5.56% decrease, closing price 590.000 (+0.68%) [2] - Anta Sports (02020): -697 million, -40.49% decrease, closing price 92.450 (+2.72%) [2] - Rongchang Biopharmaceutical (09995): -584 million, -33.65% decrease, closing price 77.450 (+13.65%) [2] - Other notable stocks include Meituan-W (03690) with -387 million and China Construction Bank (00939) with -366 million [2] Net Inflow Ratio Rankings - The top stocks by net inflow ratio include: - Datang Renewable (01798): 74.45%, net inflow of 14.5175 million, closing price 2.360 (+0.85%) [3] - Shenzhen Expressway (00548): 50.53%, net inflow of 8.719 million, closing price 7.020 (0.00%) [3] - Bosideng (03998): 50.23%, net inflow of 6.728 million, closing price 4.630 (+0.65%) [3]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Group 1 - WuXi Biologics announced the successful completion of pilot-scale end-to-end automated continuous production using its high-efficiency continuous perfusion production technology platform WuXiUP, which will be further promoted in major GMP production bases to enhance efficiency and flexibility in accelerating the entire process from R&D to commercialization of biopharmaceuticals [1] Group 2 - As of August 14, 2025, WuXi Biologics' stock price reached 30.7 HKD, successfully surpassing the 10-day moving average of 30.69 HKD and breaking through the 30-day moving average of 29.25 HKD, indicating a strengthening short-term technical trend [2] - The stock is currently challenging an important resistance level at 33.8 HKD, and if it breaks through, it will open up further upward potential [2][6] Group 3 - Technical indicators show a "buy" signal for WuXi Biologics, with a strength index of 10, and the MACD indicator maintaining a buy signal, indicating a positive medium-term trend [3] - The RSI indicator is at 62, in a neutral to strong zone, suggesting further upward potential, while the CCI indicator is in a neutral zone [3] Group 4 - Recent performance of derivative products related to WuXi Biologics has been impressive, with Societe Generale's bull certificate recording a 43% increase when the underlying stock rose by 6.16%, showcasing the explosive potential of bull certificates in trending markets [7] - HSBC's bull certificate also performed well, increasing by 41% [7] Group 5 - For investors optimistic about the market, HSBC's call option 14447 offers a leverage of 2.2 times with an exercise price of 29.15 HKD, which can effectively reduce holding costs [10] - UBS's call option 15586 is also noteworthy, suitable for investors expecting a breakout [10] Group 6 - The current stock price is facing critical technical levels, with support at 29.1 HKD and stronger support at 27.3 HKD, while the upper resistance is at 33.8 HKD, which is a psychological barrier [6] - If the stock can effectively break through this resistance, it will challenge a higher target of 35.5 HKD [6]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (74.81%), Gree Power Environmental (69.75%), and China Shenhua (68.33%) [1] - Xiaomi Group-W, Alibaba-W, and Tencent Holdings saw the largest increases in holding amounts over the last five trading days, with increases of +32.27 billion, +16.94 billion, and +11.40 billion respectively [1] - Kuaishou-W, WuXi Biologics, and Innovent Biologics experienced the largest decreases in holding amounts, with reductions of -29.14 billion, -16.60 billion, and -7.44 billion respectively [2] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding ratio of 74.81% with 10.384 billion shares [1] - Gree Power Environmental (01330) has a holding ratio of 69.75% with 0.282 billion shares [1] - China Shenhua (01088) has a holding ratio of 68.33% with 2.308 billion shares [1] Group 2: Recent Increases in Holdings - Xiaomi Group-W (01810) increased by +32.27 billion with a change of +60.65 million shares [1] - Alibaba-W (09988) increased by +16.94 billion with a change of +13.91 million shares [1] - Tencent Holdings (00700) increased by +11.40 billion with a change of +1.93 million shares [1] Group 3: Recent Decreases in Holdings - Kuaishou-W (01024) decreased by -29.14 billion with a change of -38.75 million shares [2] - WuXi Biologics (02269) decreased by -16.60 billion with a change of -53.86 million shares [2] - Innovent Biologics (01801) decreased by -7.44 billion with a change of -7.75 million shares [2]

8月14日恒生指数下跌0.37%，报收25519.32点，全天南向资金通过港股通渠道合计净买入10.34亿港 元。 证券时报·数据宝统计，8月14日港股通全天合计成交金额为1475.43亿港元，成交净买入10.34亿港元。 具体来看，沪市港股通成交金额927.12亿港元，成交净买入16.45亿港元；深市港股通成交金额548.31亿 港元，成交净卖出6.11亿港元。 成交活跃股方面，沪市港股通前十大成交活跃股中，腾讯控股成交额为60.03亿港元，成交金额居首； 其次是阿里巴巴-W、中芯国际，成交金额分别为36.89亿港元、36.59亿港元。以净买卖金额统计，中国 人寿净买入额为13.53亿港元，净买入金额居首，该股收盘股价上涨3.60%。净卖出金额最多的是腾讯控 股，净卖出6.78亿港元，收盘股价上涨0.68%。 深市港股通前十大成交活跃股中，成交额居首的是腾讯控股，成交金额41.88亿港元；其次是中芯国 际、阿里巴巴-W，成交金额分别为21.29亿港元、21.23亿港元。以净买卖金额统计，有5只股为净买 入，净买入金额最多的是阿里巴巴-W，净买入3.13亿港元，该股收盘下跌1.54%。净卖出金额最多的是 腾讯 ...

Summary of Key Points Core Viewpoint - On August 14, southbound funds recorded a transaction volume of 147.543 billion HKD, with a net inflow of approximately 1.034 billion HKD, indicating active trading in the Hong Kong stock market. Group 1: Net Inflows - Significant net purchases were made in the following companies: - China Life (02628.HK) with a net inflow of 1.353 billion HKD, showing a price increase of 3.60% [2] - Alibaba-W (09988.HK) with a net inflow of 1.42 billion HKD from the Shanghai-Hong Kong Stock Connect and 3.13 billion HKD from the Shenzhen-Hong Kong Stock Connect, despite a price drop of 1.54% [3] - Li Auto-W (02015.HK) with a net inflow of 3.52 billion HKD, experiencing a decline of 1.60% [4] - Sangfor Technologies (01530.HK) with a net inflow of 3.04 billion HKD, increasing by 2.83% [5] - CanSino Biologics (09926.HK) with a net inflow of 2.22 billion HKD, rising by 4.19% [6] - SMIC (00981.HK) with a net inflow of 2.55 billion HKD from the Shenzhen-Hong Kong Stock Connect, despite a slight decrease of 0.10% [7] Group 2: Net Outflows - Major net sales were observed in the following companies: - Tencent Holdings (00700.HK) with a net outflow of 677.8123 million HKD from the Shanghai-Hong Kong Stock Connect and 519.1757 million HKD from the Shenzhen-Hong Kong Stock Connect, with a price increase of 0.68% [8] - Meituan-W (03690.HK) with a net outflow of 141.0263 million HKD from the Shanghai-Hong Kong Stock Connect and 245.3153 million HKD from the Shenzhen-Hong Kong Stock Connect, showing a slight increase of 0.08% [9] - Crystal International (02228.HK) with a net outflow of 134.2188 million HKD from the Shanghai-Hong Kong Stock Connect and 120.6194 million HKD from the Shenzhen-Hong Kong Stock Connect, despite a significant rise of 11.61% [9] - WuXi Biologics (02269.HK) with a net outflow of 18.83193 million HKD from the Shenzhen-Hong Kong Stock Connect, with a minor price increase of 0.06% [9]

Group 1 - The core viewpoint of the article highlights the significant performance of the China Securities Hong Kong 100 Healthcare Index, which has seen a remarkable increase of 21.00% in the past month, 52.68% in the past three months, and 95.84% year-to-date [1] - The index is categorized based on the China Securities industry classification standards, with a base date of December 31, 2004, and a base point of 1000.0 [1] - The index is fully composed of securities listed on the Hong Kong Stock Exchange, with the chemical drugs sector accounting for 54.75%, biopharmaceuticals for 18.73%, pharmaceutical and biotechnology services for 14.45%, and medical commerce and services for 12.07% [1] Group 2 - The index samples are adjusted biannually, specifically on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments under special circumstances [2] - Adjustments to the index samples occur in response to changes in the parent index, special events affecting industry classification, or the delisting of sample companies [2]

（原标题：港股异动 | 药明生物(02269)盘中涨超3% 宣布WuXiUP?成功实现中试规模全自动化原液连续生产） 智通财经APP获悉，药明生物(02269)盘中涨超3%，截至发稿，涨2.53%，报31.54港元，成交额8.36亿港元。 消息面上，据药明生物官微消息，8月12日，公司宣布，其超高效连续灌流生产技术平台WuXiUP成功完成中试规模的端到端全自动化原液连续生 产，未来将进一步在主要GMP生产基地推广应用，以更高效、更灵活的技术能力，赋能客户加速生物药从研发到商业化的全进程。 据介绍，WuXiUP全自动连续生产线通过全线集成自动化系统，可实现24/7小时不间断高效运转，大幅减少人工操作环节，降低产品质量风险，提 升生产效率。WuXiUP上游总时长24天的连续细胞培养总产量突破110 g/L，单日产量最高可达7.6 g/L，在同类工艺中处于领先水平。下游工艺 中，平台引入两步高效膜层析技术，相较传统树脂填料，其传质速度更快，实现产能5-10倍的跨越式提升。 ...

据介绍，WuXiUP全自动连续生产线通过全线集成自动化系统，可实现24/7小时不间断高效运转，大幅 减少人工操作环节，降低产品质量风险，提升生产效率。WuXiUP上游总时长24天的连续细胞培养总产 量突破110g/L，单日产量最高可达7.6g/L，在同类工艺中处于领先水平。下游工艺中，平台引入两步高 效膜层析技术，相较传统树脂填料，其传质速度更快，实现产能5-10倍的跨越式提升。 消息面上，据药明生物官微消息，8月12日，公司宣布，其超高效连续灌流生产技术平台WuXiUP成功 完成中试规模的端到端全自动化原液连续生产，未来将进一步在主要GMP生产基地推广应用，以更高 效、更灵活的技术能力，赋能客户加速生物药从研发到商业化的全进程。 药明生物(02269)盘中涨超3%，截至发稿，涨2.53%，报31.54港元，成交额8.36亿港元。 ...